Rasna Therapeutics Stock Performance
| RASP Stock | USD 0 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Rasna Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rasna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Rasna Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 10.8 K |
Rasna |
Rasna Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.40 in Rasna Therapeutics on September 24, 2024 and sell it today you would earn a total of 0.00 from holding Rasna Therapeutics or generate 0.0% return on investment over 90 days. Rasna Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Rasna, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rasna Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rasna Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Rasna Therapeutics, and traders can use it to determine the average amount a Rasna Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RASP |
Based on monthly moving average Rasna Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rasna Therapeutics by adding Rasna Therapeutics to a well-diversified portfolio.
Rasna Therapeutics Fundamentals Growth
Rasna Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Rasna Therapeutics, and Rasna Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rasna Pink Sheet performance.
| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 771.81 M | |||
| Price To Book | 0.31 X | |||
| EBITDA | 254.41 K | |||
| Cash And Equivalents | 10.52 K | |||
| Total Debt | 91.97 K | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (312.66 K) | |||
| Total Asset | 85.28 K | |||
About Rasna Therapeutics Performance
Assessing Rasna Therapeutics' fundamental ratios provides investors with valuable insights into Rasna Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Rasna Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Rasna Therapeutics performance evaluation
Checking the ongoing alerts about Rasna Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Rasna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rasna Therapeutics generated a negative expected return over the last 90 days | |
| Rasna Therapeutics has some characteristics of a very speculative penny stock | |
| Rasna Therapeutics currently holds 91.97 K in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Rasna Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rasna Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Rasna Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rasna Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rasna to invest in growth at high rates of return. When we think about Rasna Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (686.59 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rasna Therapeutics currently holds about 10.52 K in cash with (312.66 K) of positive cash flow from operations. | |
| Roughly 85.0% of Rasna Therapeutics outstanding shares are owned by corporate insiders |
- Analyzing Rasna Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rasna Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rasna Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rasna Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rasna Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rasna Therapeutics' pink sheet. These opinions can provide insight into Rasna Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.